A simple blood test that measures the number of lymphocytes, a type of white blood cell in the body, may predict whether people who have relapsed multiple myeloma are going to respond well to CAR-T ...
Disease response at apheresis and association with long-term outcomes following CAR-T cells for relapsed/refractory multiple myeloma (RRMM). Cumulative incidence (%) and 95% CI of SPM at 24 months.
Apixaban versus warfarin for primary thromboprophylaxis in patients with multiple myeloma undergoing immunomodulatory treatment. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results